ClinicalTrials.gg
CompletedNCT07841028Updated Sep 25, 2026

Incision-Parallel Double-Layer Non-Locking Versus Single-Layer Locked Uterine Closure After Primary Caesarean Delivery: A Randomized Controlled Trial

An interventional study of Single-Layer Locked Uterine Closure and Double-Layer Incision-Parallel Nonlocking Uterine Closure in Cesarean Scar Defect (Isthmococele), sponsored by Onur Karaaslan. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Onur Karaaslan · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Jun 2024, registered Sep 2026).
Updated Sep 25, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Cicatrix with a site in Turkey — 4 open to participants now, 4 under way, none of them phase 3. Cicatrix · Turkey.

Enrollment
11th of 14
60 · median 95
Started
2024
with 1 other
No phase
14 of 18
4 open now
Registered
18th of 18
by date

Among the 18 studies in Cicatrix with a site in Turkey, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2024, is one of 14 with no phase, and was the 18th registered.

Cicatrix

616 studies on the registry are indexed under Cicatrix; 117 are open to participants now.

Browse Cicatrix studies →

Open to participants now

4 of the 18 studies in Cicatrix with a site in Turkey are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Cicatrix with a site in Turkey, or all of them as a file.
02

Study summary

This randomized controlled trial was conducted to compare two uterine closure techniques in women undergoing primary cesarean delivery. The study evaluated whether the technique used to close the uterine incision affects the development and characteristics of cesarean scar defects (CSD).

Participants were randomly assigned in a 1:1 ratio to either a conventional single-layer locked continuous uterine closure technique or a double-layer, incision-parallel, nonlocking continuous closure technique. Cesarean scar healing was evaluated at least three months after delivery using transvaginal ultrasonography. The primary outcome was the presence of a cesarean scar defect. Additional ultrasound measurements were used to evaluate the morphology of the cesarean scar and residual myometrial thickness.

03

Conditions studied

  • Cesarean Scar Defect (Isthmococele)

Browse trials for

Keywords

  • Cesarean scar defect
  • Cesarean scar niche
  • Residual myometrial thickness
  • Uterine closure
  • Locked suture
  • Nonlocking suture
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age 18-45 years Undergoing first cesarean delivery Early-term, term, or post-term pregnancy Elective or emergency indication for cesarean delivery Provided written

Exclusion criteria

Exclusion Criteria:

Previous cesarean delivery Congenital uterine anomaly Chronic anemia Uncontrolled gestational or pregestational diabetes mellitus Uncontrolled hypertension Severe preeclampsia >30 kg/m² Active labor lasting >5 hours Cervical dilatation >5 cm at cesarean delivery

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Single-Layer Locked Uterine Closure

    Participants underwent uterine incision closure using a single-layer locked continuous suturing technique.

    Procedure: Single-Layer Locked Uterine Closure

  • Experimental
    Double-Layer Nonlocking Uterine Closure

    Participants underwent uterine incision closure using a double-layer, incision-parallel, nonlocking continuous suturing technique.

    Procedure: Double-Layer Incision-Parallel Nonlocking Uterine Closure

Interventions

  • ProcedureSingle-Layer Locked Uterine Closure

    Uterine closure was performed using a single-layer locked continuous suturing technique after cesarean delivery.

  • ProcedureDouble-Layer Incision-Parallel Nonlocking Uterine Closure

    Uterine closure was performed using a double-layer, incision-parallel, continuous nonlocking suturing technique. Primary corner sutures were placed at both ends of the uterine incision. In the first layer, the lower-segment myometrium was approximated with full-thickness nonlocking sutures placed parallel to the incision, with corresponding bites taken from the upper segment at the same level. The second layer consisted of continuous nonlocking approximation of the serosal-subserosal tissue.

06

What researchers measure

Primary outcomes

  1. Incidence of Cesarean Scar Defect

    Cesarean scar defect (CSD) was assessed by transvaginal ultrasonography and defined as a visible hypoechoic indentation at the site of the cesarean scar with a depth of at least 2 mm.

    Time frame: At least 3 months after cesarean delivery

Secondary outcomes

  1. Cesarean Scar Morphometric Measurements

    Cesarean scar morphology was assessed by transvaginal ultrasonography. Measurements included scar indentation depth and length, residual myometrial thickness (RMT), adjacent myometrial thickness (AMT), uterovesical fold distance, vesicovaginal fold distance, and the distance between the scar indentation and the external cervical os. Measurements were expressed in millimeters. Scar indentation morphology was also recorded. When no indentation was visible, indentation depth and length were recorded as 0 mm, and external os distance was considered not applicable.

    Time frame: At least 3 months after cesarean delivery

  2. Perioperative Hemoglobin Change

    Hemoglobin levels were measured preoperatively and on postoperative day 1. Hemoglobin reduction was calculated as the preoperative hemoglobin value minus the postoperative day-1 value and was expressed in g/dL.

    Time frame: From preoperative assessment to postoperative day 1.

Other outcomes

  1. Self-Reported Postpartum Symptoms

    Self-reported symptoms were categorized as no symptoms, pain-related symptoms, dyspareunia, abnormal bleeding or spotting, and other postoperative symptoms.

    Time frame: At least 3 months after cesarean delivery

07

Study locations

1 site
  • Van Yuzuncu Yil University Faculty of Medicine
    Van, Van 65000, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be publicly shared due to participant confidentiality and ethical considerations.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Feb 2025, 7 months.

Of 175 non-industry interventional studies with no phase under Cicatrix, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's 7 months is below that.

Counting every sponsor, half of 208 studies reached it within 18 months; a quarter within 8 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2026
First posted
Sep 25, 2026
StartActual
Jun 17, 2024
Primary completionActual
Feb 15, 2025
CompletionActual
Feb 15, 2025
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07841028
Lead sponsor
Onur Karaaslan
Responsible party
Onur Karaaslan (Associate Professor of Obstetrics and Gynecology, Yuzuncu Yil University) — Sponsor-investigator
First posted
Sep 25, 2026
Start date
Jun 17, 2024
Primary completion
Feb 15, 2025
Completion
Feb 15, 2025
Last update
Sep 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion